Clinical Trials Browser

Has results × Pemetrexed × Genitourinary × Clear all

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02693717 2021-05-20

Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer

Phase 2 Terminated

7 enrolled 5 charts

Genitourinary

Carcinoma, Transitional Cell

NCT00216099 2016-07-29

Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer

Phase 2 Completed

49 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT01338792 2014-03-10

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

Phase 2 Completed

47 enrolled 10 charts

Genitourinary

Prostatic Neoplasms

NCT00491075 2013-04-24

Pemetrexed Plus Gemcitabine in Renal Cell Cancer

Phase 2 Terminated

16 enrolled 7 charts

Genitourinary

Carcinoma, Renal Cell

NCT00374868 2010-11-04

Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)

Phase 1/2 Completed

59 enrolled 17 charts

Genitourinary

Urologic Neoplasms

Clinical Trials

PIVOT-02

Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer

Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

Pemetrexed Plus Gemcitabine in Renal Cell Cancer

Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)